These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15038826)

  • 1. Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation.
    Perez N; Bigey P; Scherman D; Danos O; Piechaczyk M; Pelegrin M
    Genet Vaccines Ther; 2004 Mar; 2(1):2. PubMed ID: 15038826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High in vivo production of a model monoclonal antibody on adenoviral gene transfer.
    Noël D; Pelegrin M; Kramer S; Jacquet C; Skander N; Piechaczyk M
    Hum Gene Ther; 2002 Aug; 13(12):1483-93. PubMed ID: 12215269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin as a potential organ for ectopic monoclonal antibody production.
    Noël D; Dazard JE; Pelegrin M; Jacquet C; Piechaczyk M
    J Invest Dermatol; 2002 Feb; 118(2):288-94. PubMed ID: 11841546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody-based genetic immunotherapy.
    Pelegrin M; Gros L; Dreja H; Piechaczyk M
    Curr Gene Ther; 2004 Sep; 4(3):347-56. PubMed ID: 15384948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in monoclonal antibody-based therapies.
    Samaranayake H; Wirth T; Schenkwein D; Räty JK; Ylä-Herttuala S
    Ann Med; 2009; 41(5):322-31. PubMed ID: 19234897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections.
    Andrews CD; Luo Y; Sun M; Yu J; Goff AJ; Glass PJ; Padte NN; Huang Y; Ho DD
    Mol Ther Methods Clin Dev; 2017 Dec; 7():74-82. PubMed ID: 29034261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ production of therapeutic monoclonal antibodies.
    Suscovich TJ; Alter G
    Expert Rev Vaccines; 2015 Feb; 14(2):205-19. PubMed ID: 25578347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mechanism of naked DNA uptake and expression.
    Wolff JA; Budker V
    Adv Genet; 2005; 54():3-20. PubMed ID: 16096005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts.
    Noël D; Pelegrin M; Brockly F; Lund AH; Piechaczyk M
    J Invest Dermatol; 2000 Oct; 115(4):740-5. PubMed ID: 10998153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient laboratory-scale production of monoclonal antibodies using membrane-based high-density cell culture technology.
    Trebak M; Chong JM; Herlyn D; Speicher DW
    J Immunol Methods; 1999 Nov; 230(1-2):59-70. PubMed ID: 10594354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled release of monoclonal antibodies from poly-l-lysine-coated alginate spheres within a scaffolded implant mitigates autoimmune responses to transplanted islets and limits systemic antibody toxicity.
    Vernon RB; Gooden MD; Preisinger A; Gebe JA
    Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():390-398. PubMed ID: 30274071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells.
    Noël D; Pelegrin M; Marin M; Biard-Piechaczyk M; Ourlin JC; Mani JC; Piechaczyk M
    Hum Gene Ther; 1997 Jul; 8(10):1219-29. PubMed ID: 9215739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies.
    Pelegrin M; Marin M; Oates A; Noël D; Saller R; Salmons B; Piechaczyk M
    Hum Gene Ther; 2000 Jul; 11(10):1407-15. PubMed ID: 10910138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive immune-prophylaxis against influenza virus infection by the expression of neutralizing anti-hemagglutinin monoclonal antibodies from plasmids.
    Yamazaki T; Nagashima M; Ninomiya D; Arai Y; Teshima Y; Fujimoto A; Ainai A; Hasegawa H; Chiba J
    Jpn J Infect Dis; 2011; 64(1):40-9. PubMed ID: 21266754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged
    Hollevoet K; De Smidt E; Geukens N; Declerck P
    Oncotarget; 2018 Mar; 9(17):13623-13636. PubMed ID: 29568382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies produced by muscle after plasmid injection and electroporation.
    Tjelle TE; Corthay A; Lunde E; Sandlie I; Michaelsen TE; Mathiesen I; Bogen B
    Mol Ther; 2004 Mar; 9(3):328-36. PubMed ID: 15006599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electroporation for gene transfer to skeletal muscles: current status.
    McMahon JM; Wells DJ
    BioDrugs; 2004; 18(3):155-65. PubMed ID: 15161333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering human cells for in vivo secretion of antibody and non-antibody therapeutic proteins.
    Sánchez-Martín D; Sanz L; Álvarez-Vallina L
    Curr Opin Biotechnol; 2011 Dec; 22(6):924-30. PubMed ID: 21435857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically engineered antibodies in gene transfer and gene therapy.
    Pelegrin M; Marin M; Noël D; Piechaczyk M
    Hum Gene Ther; 1998 Oct; 9(15):2165-75. PubMed ID: 9794201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.